AIRA SECURITIES PUBLIC COMPANY LIMITED

Global Investment

Keep Eyes On

TransMedics Group Inc.

NASDAQ : TMDX

12M Target Price (Bloomberg)
103.13 USD

TransMedics is a medical technology company focused on transforming organ transplant therapy for patient suffering from end-stage organ failure, specifically targeting the heart, lung, and liver markets.

TMDX primary product is the Organ Care System (OCS), designed to preserve organs for a longer duration compared to traditional methods. OCS had has received FDA Pre-Market Approval for heart, lung, and liver transplants.

TMDX operates a National OCS Program (NOP), providing outsourced organ retrieval and management services to transplant programs. across the United States by plane which become one of their cost

As of Mar12nd TMDX result came out strong performance in 4Q24, surpassing expectations with sales of $121.6 million (50% YoY) and beating consensus mainly form product revenues, a robust performance in domestic liver and heart sales, while lung sales fell short of expectations

For 2025F company still maintained their guidance for 20-25% revenue growth includes expected contributions from clinical trial revenues linked to FDA approvals, But still uncertainty due to current delays at the FDA

Overall, we believe TransMedics has favorable growth potential supported by strong product performance and continued investments in R&D, while remaining cautious of the potential downsides associated with uncertainties regarding FDA approvals.

Fundamental Outlook

LAST PRICE	67.65
MARKET CAP (Bil.$)	2.28
P/E	66.98
P/BV	9.95
Dividend Yield (%)	N.A

Technical Outlook

Support	54.00	34.00
Resistant	82.00	100.00
Take Profit	100.00	115.00
Stop <	52.00	

Revenue – Net Profit - %Growth (yoy)



เปิดบัญชีลงทุน Global Trade กับ AIRA ได้ที่นี่

AIRA Research
ณรงค์เดช จันทรไพศาล #066063 Tel. 022681717
พีรพล สุรัตนวนิช ผู้ช่วยนักวิเคราะห์
วรภัทร เบญจาพุทธารักษ์ ผู้ช่วยนักวิเคราะห์